- Policy
- COVID-19 drug Paxlovid’s price likely to be based on Japan
- by Lee, Tak-Sun Sep 6, 2024 05:48am
- The insurance ceiling price of Pfizer's COVID-19 drug Paxlovid is likely to be set at around KRW 900,000 in Korea. This is similar to its price in Japan. Japan is said to have the lowest price for Paxlovid among the A8 countries. According to industry sources on the 4th, Paxlovid passed the Drug Reimbursement Evaluation Committee (DREC
- Company
- K-made new anti-cancer drugs to unveil at conference
- by Son, Hyung-Min Sep 6, 2024 05:48am
- Korean pharmaceutical and biotech industry will unveil their positive clinical trial results at the world's largest cancer conference. The clinical outcomes of various new drug candidates from the South Korea-based pharmaceutical and biotech companies will be presented at the European Society for Medical Oncology (ESMO) Congress (ESMO 2024
- Company
- Padcev’s reimb complex due to considerations
- by Hwang, Byung-woo Sep 5, 2024 05:52am
- Astellas Pharma Korea is continuing complex calculations for health insurance reimbursement listing of its metastatic urothelial cell carcinoma drug Padcev (enfortumab vedotin) in Korea. The reimbursement is being discussed for the second-line monotherapy indication, which was first approved. However, as the company is seeking reimbursement f
- Company
- Will Imfinzi pass CDDC review with biliary tract cancer data
- by Moon, sung-ho Sep 5, 2024 05:52am
- Biliary tract cancer is known to have the highest mortality and incidence rates in Korea in the world. It is also one of the most difficult cancers to treat in Korea due to the limited options, or ‘weapons’ available to doctors in practice. However, immuno-oncology drugs are being approved for the first-line treatment of biliary tract cance
- Opinion
- [Reporter’s View] Vaccine sovereignty only during epidemics
- by Son, Hyung-Min Sep 5, 2024 05:51am
- The Korea Disease Control and Prevention Agency recently announced that it will support messenger ribonucleic acid (mRNA) vaccines in preparation for the next pandemic. The government will support research and development from preclinical to Phase III trials, focusing on companies with the potential to localize mRNA vaccine platforms. Ca
- Company
- New lymphoma drug 'Columvi' reapplies for reimbursement
- by Eo, Yun-Ho Sep 5, 2024 05:51am
- 'Columvi,' a first-in-class bispecific antibody for lymphoma treatment, will make another attempt to be considered for reimbursement listing. According to industry sources, Roche Korea has recently submitted a reimbursement application for the CD20·CD3 bispecific antibody Diffuse Large B-Cell Lymphoma (DLBCL) treatment Columvi (glofitama
- Company
- More treatment options for rheumatoid arthritis available
- by Hwang, Byung-woo Sep 5, 2024 05:51am
- "Patients with rheumatoid arthritis differ by age, duration of illness, accompanying disease, self-injection capability, risk factor for complications, and economic status. Therefore, drug selection considering an individual's condition is crucial." Rheumatoid arthritis is caused by abnormally activated immune cells attacking joints, t
- Company
- J&J appoints Christian Rodseth as new Managing Director
- by Hwang, Byung-woo Sep 5, 2024 05:51am
- Janssen Korea, a subsidiary of Johnson and Johnson (J&J)'s pharmaceutical division in South Korea, announced on September 4th that Christian Rodseth was appointed as the new Managing Director for J&J's pharmaceutical division in North Asia as of September 2nd. As the CEO of Janssen Korea and Managing Director for J&J's pharmaceutical div
- Policy
- ‘Policy support enabled the prompt approval of Envlo’
- by Lee, Hye-Kyung Sep 4, 2024 05:49am
- The backstory of Daewoong Pharmaceutical's Envlo 0.3mg (enavogliflozin), which is a representative success case of the MFDS’s expedited review process, was introduced recently. The government’s policy support for the commercialization of innovative products was what enabled Envlo’s clinical trial to approval in just 5 years. In general
- Company
- New drug Voranigo receives orphan drug designation in Korea
- by Eo, Yun-Ho Sep 4, 2024 05:49am
- Voranigo, the first new malignant brain tumor drug introduced in 20 years, has received an orphan drug designation in Korea. The Ministry of Food and Drug Safety announced so through an official orphan drug designation notice on the 3rd. Specifically, the drug is for the treatment of IDH-mutated diffuse glioma. Voranigo can be used to
